Dr. Kerin Bess Adelson, MD

Dr. Adelson practices at Michigan Retina Center in Dearborn, Michigan.

Dr. Adelson's NPI, 1285846790, was assigned on May 4, 2007. Dr. Adelson graduated from Yale School of Medicine in 2000. Dr. Adelson holds Texas license U3139.

Dr. Adelson's primary practice is Michigan Retina Center, at 25230 Michigan Ave, Dearborn, MI 48124 in Wayne County. The practice phone is (313) 441-2227.

Dr. Adelson's primary practice is Michigan Retina Center in Dearborn, Michigan. Dr. Adelson is also affiliated with The University of Texas MD Anderson Cancer Center. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Adelson practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Adelson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Adelson is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Adelson's licenses on file in 12 states: Texas, Florida, Arizona, Washington, Alabama, Georgia, Louisiana, Mississippi, Oklahoma, Tennessee, Connecticut and New York.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Adelson treats.

CMS data shows 18 Medicare services from Dr. Adelson across 1 procedure code in 2023, all of them office visits. Medicare paid $1,084 for them. Every service was in a facility, such as a hospital, rather than an office.

Across all payers, Dmand AI patient panel data puts Dr. Adelson's median patient age at 70, with 71% women.

In 2024, Dr. Adelson wrote 13 Medicare Part D claims. 100% of them were for generic drugs. They cover 1 drug, with $888 in total drug cost. In 2022, CMS named 59 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Adelson for performance year 2024, reported as part of a group. Dr. Adelson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Adelson as offering telehealth.

Dmand AI links 72 papers to Dr. Adelson, published from 2005 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Medical Oncology. Dr. Adelson has published most often in J Oncol Pract. Dr. Adelson's most frequent co-authors are Cary E. Gross, MD, Cardinale B. Smith, MD, PhD and Lajos Pusztai, MD.

Dmand AI links Dr. Adelson to 5 clinical trials, 3 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Lobular.

CMS Open Payments shows 31 general payments to Dr. Adelson from 8 drug and device companies from 2017 to 2022. Consulting fees make up the largest share, 71% of the total. AstraZeneca Pharmaceuticals LP paid the most, $8,200.

Dr. Adelson graduated from Yale School of Medicine in 2000.

Dr. Adelson is in network with 6 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.